As Sandra Lee suggested, race and ethnicity are now seen “as major axes for stratifying drug response” in the context of breast cancer pharmacogenomics, with different types of breast cancer tumors related to hormone receptor status thought to exist at variable frequencies among different populations defined as “European, Asian and African”(2013:160–161). This evidence concerns the gene NR4A1 and breast carcinoma.